926 related articles for article (PubMed ID: 28548309)
1. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
[TBL] [Abstract][Full Text] [Related]
2. Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study.
Delgado-Alvarado M; Dacosta-Aguayo R; Navalpotro-Gómez I; Gago B; Gorostidi A; Jiménez-Urbieta H; Quiroga-Varela A; Ruiz-Martínez J; Bergareche A; Rodríguez-Oroz MC
Mov Disord; 2018 Nov; 33(11):1809-1813. PubMed ID: 30423201
[TBL] [Abstract][Full Text] [Related]
3. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
[TBL] [Abstract][Full Text] [Related]
4. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
Hall S; Surova Y; Öhrfelt A; ; Blennow K; Zetterberg H; Hansson O
Mov Disord; 2016 Jun; 31(6):898-905. PubMed ID: 26878815
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
[TBL] [Abstract][Full Text] [Related]
9. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Miki A; Ohashi H; Owan Y; Saito Y; Yano S; Tsukie T; Ikeuchi T; Ono K
BMC Neurol; 2019 Jun; 19(1):113. PubMed ID: 31164098
[TBL] [Abstract][Full Text] [Related]
10. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
[TBL] [Abstract][Full Text] [Related]
12. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
[TBL] [Abstract][Full Text] [Related]
13. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
Goldman JG; Andrews H; Amara A; Naito A; Alcalay RN; Shaw LM; Taylor P; Xie T; Tuite P; Henchcliffe C; Hogarth P; Frank S; Saint-Hilaire MH; Frasier M; Arnedo V; Reimer AN; Sutherland M; Swanson-Fischer C; Gwinn K; ; Kang UJ
Mov Disord; 2018 Feb; 33(2):282-288. PubMed ID: 29205509
[TBL] [Abstract][Full Text] [Related]
15. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
16. CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.
Oosterveld LP; Kuiper TI; Majbour NK; Verberk IMW; van Dijk KD; Twisk JWR; El-Agnaf OM; Teunissen CE; Weinstein HC; Klein M; Berendse HW; van de Berg WDJ
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198266
[TBL] [Abstract][Full Text] [Related]
17. CSF biomarkers and clinical progression of Parkinson disease.
Hall S; Surova Y; Öhrfelt A; Zetterberg H; Lindqvist D; Hansson O
Neurology; 2015 Jan; 84(1):57-63. PubMed ID: 25411441
[TBL] [Abstract][Full Text] [Related]
18. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A
J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175
[TBL] [Abstract][Full Text] [Related]
20. Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease.
Akhtar RS; Licata JP; Luk KC; Shaw LM; Trojanowski JQ; Lee VM
J Neurochem; 2018 Jun; 145(6):489-503. PubMed ID: 29500813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]